Clinical trials: Trypanosoma Brucei Gambiense; Infection
Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Acoziborole has been studied in an open-label pivotal Phase II/III trial (DNDi-OXA-02-HAT) in the DRC and Guinea. As the numbers of reported cases diminish, resources for surveillance and specialised screening will also taper.
- Conditions
- Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection, Sleeping Sickness
- Trial name
- OXA005 (NCT05433350)
- Testing
- Acoziborole
- Where
- 6 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 35 people
- Sponsor
- Drugs for Neglected Diseases
African Trypanosomiases, West African; Trypanosomiasis
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
The study determines the diagnostic performance and cost of rapid diagnostic tests (RDTs) performed on human African trypanosomiasis clinical suspects in peripheral health centres, whether or not followed by serological and/or…
- Conditions
- African Trypanosomiases, West African; Trypanosomiasis, Sleeping Sickness; West African, Trypanosoma Brucei Gambiense; Infection
- Trial name
- DiTECT-WP2 (NCT03356665)
- Testing
- Rapid diagnostic test (RDT), Serological and molecular tests on DBS
- Where
- 3 sites in Côte d’Ivoire, Democratic Republic of the Congo and 1 more
- Volunteers
- 10,700 people
- Sponsor
- Institut de Recherche pour le Developpement
Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Human African trypanosomiasis (HAT) or sleeping sickness is a tropical disease which is endemic in sub-Saharan Africa. Most cases of HAT are due to the parasite Trypanosoma brucei gambiense (T.b.
- Conditions
- Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection, Sleeping Sickness
- Trial name
- OXA004 (NCT05256017)
- Testing
- Acoziborole
- Where
- 7 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 1,208 people
- Sponsor
- Drugs for Neglected Diseases
African Trypanosomiasis
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers.
- Trial name
- NCT00803933
- Testing
- DB289, Pentamidine
- Where
- 2 sites in Republic of the Congo
- Volunteers
- 111 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Human African Trypanosomiasis, Sleeping Sickness
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
This study evaluates and compares the diagnostic specificity of 5 serological field tests for screening of the population at risk for human African trypanosomiasis due to Trypanosoma brucei gambiense.
- Conditions
- Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection, West African Sleeping Sickness
- Trial name
- SpeSerTryp (NCT05466630)
- Testing
- Serological field test for HAT, malaria rapid test, Immunologic laboratory tests
- Where
- 2 sites in Côte d’Ivoire, Guinea
- Volunteers
- 1,095 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense
Stop Transmission of Gambiense Human African Trypanosomiasis
This protocol describes both the epidemiological study which aims at assessing whether over a three-year period a zero prevalence can be achieved when implementing a screen \& treat approach with acoziborole, as well as a nested…
- Trial name
- STROgHAT (NCT07789743)
- Testing
- Acoziborole
- Where
- Democratic Republic of the Congo
- Volunteers
- 2,500 people
- Sponsor
- Institute of Tropical Medicine, Belgium
African Trypanosomiasis, African; Trypanosomiasis, West
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure
The study validates the diagnostic performance of cerebrospinal fluid neopterin quantification and of blood and cerebrospinal fluid trypanosomal spliced leader RNA detection for assessing outcome after treatment of human African…
- Conditions
- African Trypanosomiasis, African; Trypanosomiasis, West, Sleeping Sickness; West African, Trypanosoma Brucei Gambiense; Infection
- Trial name
- DiTECT-WP4 (NCT03112655)
- Testing
- RNA and neopterin detection
- Where
- Democratic Republic of the Congo
- Volunteers
- 88 people
- Sponsor
- Institut de Recherche pour le Developpement
Human African Trypanosomiasis
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
Multicenter, open label, uncontrolled phase IIIb study of therapeutic use of the combination of nifurtimox and eflornithine (NECT) for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the…
- Trial name
- NECT-FIELD (NCT00906880)
- Testing
- Nifurtimox-Eflronithine Combination Treatment (NECT)
- Where
- 6 sites in Republic of the Congo
- Volunteers
- 630 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African, Gambiense Trypanosomiasis
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
The goal of this study is to assess efficacy and safety of acoziborole in adult participants with Trypanosoma brucei gambiense (T.b.
- Conditions
- Trypanosomiasis, African, Gambiense Trypanosomiasis, Sleeping Sickness
- Trial name
- OXA002 (NCT03087955)
- Testing
- Acoziborole
- Where
- 12 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 208 people
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis, Sleeping Sickness
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
This study determines the feasibility, diagnostic performance and cost for monitoring of eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of serological and molecular high throughput tests with and…
- Conditions
- Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection, West African Sleeping Sickness
- Trial name
- DiTECT-HAT-WP3 (NCT04099628)
- Testing
- Rapid diagnostic test (RDT); Serological and molecular tests on DBS
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 13,747 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Trypanosomiasis, African
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
The purpose of this study is to compare the therapeutic combination of I.V. eflornithine + oral nifurtimox to the standard IV eflornithine regimen in terms of therapeutic efficacy and clinical safety, in patients suffering from…
- Trial name
- NCT00146627
- Testing
- Eflornithine, Nifurtimox
- Where
- 4 sites in Democratic Republic of the Congo, Republic of the Congo
- Volunteers
- 280 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda, in which the combination of eflornithine + nifurtimox showed very promising efficacy and safety.
- Trial name
- NECS (NCT00489658)
- Testing
- Eflornithine plus Nifurtimox combination therapy
- Where
- Uganda
- Volunteers
- 31 people
- Sponsor
- Epicentre